A new trial could help ambulances respond to emergencies more efficiently. South Central Ambulance Service NHS Foundation Trust (SCAS) is working with Ordnance Survey (OS) on the trial to maximise the ...
Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...
OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, CEO, and ...
Onctura has dosed the first subject in the Phase II OCULE-01 trial of oral roginolisib in individuals with metastatic uveal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results